Bevacizumab in the treatment of NSCLC: patient selection and perspectives

Non-small-cell lung cancer (NSCLC) represents about 85% of all lung cancers, and more than half of NSCLCs are diagnosed at an advanced stage. Chemotherapy has reached a plateau in the overall survival curve of about 10 months. Therefore, in last decade novel targeted approaches have been developed t...

Descripción completa

Detalles Bibliográficos
Autores principales: Russo, Alessia E, Priolo, Domenico, Antonelli, Giovanna, Libra, Massimo, McCubrey, James A, Ferraù, Francesco
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2017
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5733913/
https://www.ncbi.nlm.nih.gov/pubmed/29276417
http://dx.doi.org/10.2147/LCTT.S110306

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5733913/
https://www.ncbi.nlm.nih.gov/pubmed/29276417
http://dx.doi.org/10.2147/LCTT.S110306

Ejemplares similares